Variant Perception

Where We Disagree With the Market

The market is debating the wrong unit. Both the sell-side ($217 mean target, three big cuts on May 1) and Stan's bull/bear frame argue over an EV/EBITDA multiple — but at THC, 41% of consolidated net income leaves the door as USPI noncontrolling-interest distributions before any shareholder sees a dollar, and a ~$540M one-time CommonSpirit cash payment plus a $1.36B non-interest-bearing CHI note are flattering 2026 cash flow. Strip those out and the per-share-FCF compounder thesis that anchors most "buy" notes is mechanically broken in FY26 — for the first time since 2022, organic FCF-after-NCI is guided flat-to-down, and the buyback math that "compounds independent of any rerate" depends on the cash that the guide says will not be there. We also believe the Fuzzy Panda compliance tail is meaningfully underpriced because the SEC's own FOIA Exemption 7(A) refusal is a concrete signal of an active enforcement matter — a fact the market is treating as "no Wells notice = no risk." Our resolution path is dated and observable: Q2 FY26 cash bridge (Jul 22), Q3 FY26 OBBBA framing (early Nov), and the FY27 initial guide on the Q4 FY26 call (Feb 2027).

Variant Perception Scorecard

A 70 on variant strength reflects a real, materially monetizable disagreement (per-share cash mechanics distorted by the Conifer unwind, NCI leakage, and an underpriced compliance tail), but not an exotic one — sell-side targets have started moving toward us already, with three major banks cutting on May 1, 2026. Consensus clarity is high because the cuts, the ISS QualityScore, the Lone Pine / Wellington / Eminence Q4 buyer set, and the Trefis "Capital Compounder" framing are all observable. Evidence strength is high because most of our claims are deterministic — the FY26 Adj. FCF less NCI guide of $1.6–1.83B versus FY25's $1.84B actual is in the press release; the $540M CommonSpirit one-time is in the Q1 10-Q; the SEC's FOIA Exemption 7(A) refusal is on file. The decisive resolution event is the FY27 initial guide on the Q4 FY26 call (≈Feb 2027), so this is a 9-month horizon trade, not a multi-year one.

Consensus Map

The Disagreement Ledger

Disagreement #1 — Per-share FCF compounder is broken in FY26 once Conifer unwind is stripped. A consensus analyst would say Tenet retired ~$1.4B of stock in FY25 against $1.84B FCF less NCI — call it 75% payout — and a 7% buyback yield speaks for itself. Our evidence pushes back: FY26 guide for Adj. FCF less NCI is $1.6–$1.83B, BELOW FY25 actual, and Q1 OCF was supported by $540M of one-time CommonSpirit cash. If we are right, the bull's "buyback compounds at 9%/year independent of rerate" stops compounding at the FY26 step — either the pace slows or the funding shifts to debt drawdown, killing the deleveraging story. The cleanest disconfirming signal is two consecutive quarterly prints (Q2, Q3) where Adj. FCF less NCI annualizes inside the guided range AND a fresh buyback authorization is announced before $1.17B exhausts.

Disagreement #2 — Compliance tail is mispriced because the SEC's own FOIA Exemption 7(A) refusal is a real signal. Consensus reads "no Wells notice yet" as "no risk." Our evidence pushes back: Exemption 7(A) is specifically reserved for documents that would interfere with an active enforcement proceeding. Tenet/NME has paid >$2.5B in fines over 20 years in the exact coding/outlier categories the new short report alleges, and the 2003 outlier scheme was first surfaced in analyst reports before the SEC filed civil fraud charges in 2007 — a precedent pattern. If we are right, a $675–$845M reserve (3–4% of market cap) belongs in any clean DCF/SOTP, and the next 10-Q's Item 3 language is the binary. The cleanest disconfirming signal is the FY2026 10-K closing without any new disclosure plus a specific, detailed company rebuttal on the earnings call referencing hospital-level cost-report data.

Disagreement #3 — Bull and bear are fighting the wrong segment. A consensus analyst would tell you USPI's same-facility revenue trajectory in Q2 and Q3 is the decisive read. Our evidence pushes back: USPI is a bounded growth band already largely embedded in the current multiple; the real binary that swings fair value from $122 to $244 is the Hospital segment's response to OBBBA Medicaid across the four hospital states (TX, FL, AZ, MI) that have not expanded Medicaid. If we are right, the institutional move is to re-orient the watch list to hospital adjusted-admission revenue (already -1.5% Q1) and state-agency rule postings, not USPI. The cleanest disconfirming signal is two consecutive prints where hospital adj-admission revenue prints non-negative AND Texas or Florida publish OBBBA implementation rules at the gentler end of the framework.

Evidence That Changes the Odds

How This Gets Resolved

What Would Make Us Wrong

The first place we are most exposed is the per-share-FCF disagreement. Tenet has beaten every annual EBITDA, USPI EBITDA, and FCF guide since FY24 by ~$500M and the FY26 guide is conservative by design — management explicitly said they did not raise after a 23.2% margin Q1. If FY26 Adj. FCF less NCI exits the year above the high end of the guide and a fresh buyback authorization is announced before $1.17B exhausts, our claim that "the cash that funds the compounder is going down" looks too clever — the right read becomes "guide buffer," not "broken mechanic." The strongest counter-evidence already exists: Q1 FY26 Adj. FCF was $978M with the buyback running at $318M, and management has earned credibility on cash. We would need to see two clean quarters where the run-rate falls inside $1.6–$1.8B even excluding Conifer cash to keep this disagreement.

The second place we are exposed is on Fuzzy Panda. FOIA Exemption 7(A) refusals are routine when an SEC matter is open at any stage — including matters that close without action. The 18–24 month enforcement timeline means a clean 10-K through Feb 2027 is a real possibility, in which case the tail premium evaporates and we are paying for protection that did not need to be priced. The 2007 SEC outlier action took four years from inquiry to settlement; the 2025 short report is less than 12 months old. Time is on the bull's side here, not ours.

The third place we are exposed is on the segment reorientation. If the Senate clears 60 votes on the House-passed EPTC extension before November ACA open enrollment, the hospital binary partially defuses, USPI's bounded growth band still earns a reasonable multiple, and the entire variant collapses back into "the consensus is roughly right at $217." That outcome is genuinely possible — the House passed the extension 230–196 with 17 Republicans voting yes, and OBBBA has bipartisan critics in red states with rural hospital exposure.

A useful red-team summary: the bull's "$244 mean reversion" math could be exactly right if (a) the Senate passes EPTC, (b) Q2/Q3 USPI revenue holds at 6%+, (c) FY26 Adj. FCF less NCI exits at the top of the guided range, and (d) a fresh buyback authorization lands before $1.17B exhausts. Three of those four are inside management's control. Our variant view is not that this is impossible — it is that the cumulative probability of all four is meaningfully lower than what a $217 mean PT implies, because the cash and FOIA pieces are independent of management's playbook.

The first thing to watch is the Q2 FY26 cash-flow bridge on July 22, 2026 — specifically whether organic Adj. FCF less NCI (excluding any further CommonSpirit unwind cash) prints inside the FY26 guided range without a buyback step-down.